In8Bio (INAB) Cash from Financing Activities (2020 - 2026)
In8Bio (INAB) posted Cash from Financing Activities of -$195000.0 for Q1 2026, down 101.05% sequentially from $18.5 million in Q4 2025, and down 105.01% YoY from $3.9 million in Q1 2025.
In8Bio (INAB) Cash from Financing Activities (2020 - 2026) Analysis & Trends
In8Bio has reported Cash from Financing Activities for 7 years, with the latest figure at -$195000.0 in Q1 2026.
- Quarterly Cash from Financing Activities fell 105.01% year-over-year to -$195000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.5 million (up 33.76% YoY) and the FY2025 annual result came in at $28.6 million, up 101.9% from the prior year.
- Cash from Financing Activities slipped to -$195000.0 in Q1 2026 per INAB's latest filing, from $18.5 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $18.5 million in Q4 2025 and troughed at -$277000.0 in Q1 2024.
- A 5-year average of $4.6 million and a median of $1.7 million in 2023 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities surged 17253.73% in 2023, then slumped 150.64% in 2024.
- Over 5 years, Cash from Financing Activities stood at -$253000.0 in 2022, then surged by 5377.47% to $13.4 million in 2023, then declined by 16.21% to $11.2 million in 2024, then surged by 65.27% to $18.5 million in 2025, then tumbled by 101.05% to -$195000.0 in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$195000.0, $18.5 million, and $989000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | In8Bio | 24.34 Mn | 24.34 Mn | - | -51,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -51,000.00 |
| Jun 30, 2026 | -51,000.00 |
| Mar 31, 2026 | -195,000.00 |
| Mar 31, 2026 | -195,000.00 |
| Dec 31, 2025 | 18.49 Mn |
| Dec 31, 2025 | 18.49 Mn |
| Sep 30, 2025 | 989,000.00 |
| Sep 30, 2025 | 989,000.00 |
| Jun 30, 2025 | 5.27 Mn |
| Jun 30, 2025 | 5.27 Mn |
| Mar 31, 2025 | 3.89 Mn |
| Mar 31, 2025 | 3.89 Mn |
| Dec 31, 2024 | 11.19 Mn |
| Dec 31, 2024 | 11.19 Mn |
| Sep 30, 2024 | -105,000.00 |
| Sep 30, 2024 | -105,000.00 |
| Jun 30, 2024 | 3.38 Mn |
| Jun 30, 2024 | 3.38 Mn |
| Mar 31, 2024 | -277,000.00 |
| Mar 31, 2024 | -277,000.00 |